xCELLigence RTCA CardioECR Featured on the Discovery Channel's Innovations Program

1,452 views

|

May 11, 2016

Cardiomyocyte contractility, viability, and electrical activity measured in real-time.

The new xCELLigence® RTCA CardioECR instrument combines high frequency measurement of cell-induced electrical impedance with multielectrode array technology to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology.

The xCELLigence® RTCA CardioECR instrument, regularly used in combination with human iPSC-derived cardiomyocytes, enables in vitro assays that are highly predictive of drug induced cardiac liability. It offers:

• A high-throughput method for detecting functional cardiotoxicity (effects on short-term and long-term cardio beating activity) and general toxicity in vitro
• A test of integrated ion channel activity
• Data that display excellent correlation with clinical arrhythmogenic risk
• Pacing function for more tightly controlled assays
• More thorough understanding of drug mechanism of action

As broadcast on Discovery Channel's "Innovations" program 12/18/2014.

For more information, please visit: http://www.aceabio.com/product/rtca-cardioecr/

Analytical TechniquesCell ScienceDrug DiscoveryStem Cells

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.